Pharma Foods International Co., Ltd. (2929.T)
JPY 917.0
(1.1%)
JPY 917.0
(1.1%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 36.57 Billion JPY | 0.94% |
| 2023 | 36.23 Billion JPY | 16.28% |
| 2022 | 31.15 Billion JPY | 48.77% |
| 2021 | 20.94 Billion JPY | 107.44% |
| 2020 | 10.09 Billion JPY | 15.64% |
| 2019 | 8.73 Billion JPY | 37.93% |
| 2018 | 6.33 Billion JPY | 8.32% |
| 2017 | 5.84 Billion JPY | 30.66% |
| 2016 | 4.47 Billion JPY | 19.63% |
| 2015 | 3.73 Billion JPY | -4.97% |
| 2014 | 3.93 Billion JPY | 28.2% |
| 2013 | 3.06 Billion JPY | 9.83% |
| 2012 | 2.79 Billion JPY | 15.76% |
| 2011 | 2.41 Billion JPY | -1.93% |
| 2010 | 2.46 Billion JPY | -7.12% |
| 2009 | 2.65 Billion JPY | -2.72% |
| 2008 | 2.72 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 36.93 Billion JPY | -0.24% |
| 2024 Q4 | 36.57 Billion JPY | -0.97% |
| 2024 Q1 | 37.68 Billion JPY | 4.0% |
| 2024 Q2 | 37.02 Billion JPY | -1.75% |
| 2023 Q1 | 32.7 Billion JPY | 4.95% |
| 2023 FY | 36.23 Billion JPY | 16.28% |
| 2023 Q2 | 33.87 Billion JPY | 3.59% |
| 2023 Q3 | 35.46 Billion JPY | 4.69% |
| 2023 Q4 | 36.23 Billion JPY | 2.16% |
| 2022 FY | 31.15 Billion JPY | 48.77% |
| 2022 Q3 | 30.27 Billion JPY | 13.07% |
| 2022 Q4 | 31.15 Billion JPY | 2.93% |
| 2022 Q1 | 29.99 Billion JPY | 43.21% |
| 2022 Q2 | 26.77 Billion JPY | -10.73% |
| 2021 Q2 | 16.27 Billion JPY | 12.21% |
| 2021 Q4 | 20.94 Billion JPY | 16.33% |
| 2021 FY | 20.94 Billion JPY | 107.44% |
| 2021 Q1 | 14.49 Billion JPY | 43.61% |
| 2021 Q3 | 18 Billion JPY | 10.65% |
| 2020 Q3 | 9.33 Billion JPY | 18.77% |
| 2020 Q1 | 9.01 Billion JPY | 3.21% |
| 2020 FY | 10.09 Billion JPY | 15.64% |
| 2020 Q2 | 7.85 Billion JPY | -12.8% |
| 2020 Q4 | 10.09 Billion JPY | 8.18% |
| 2019 Q4 | 8.73 Billion JPY | 12.15% |
| 2019 FY | 8.73 Billion JPY | 37.93% |
| 2019 Q1 | 8.6 Billion JPY | 35.91% |
| 2019 Q2 | 7.87 Billion JPY | -8.47% |
| 2019 Q3 | 7.78 Billion JPY | -1.14% |
| 2018 Q1 | 5.95 Billion JPY | 1.83% |
| 2018 Q3 | 5.9 Billion JPY | 11.59% |
| 2018 Q2 | 5.29 Billion JPY | -11.09% |
| 2018 FY | 6.33 Billion JPY | 8.32% |
| 2018 Q4 | 6.33 Billion JPY | 7.22% |
| 2017 Q4 | 5.84 Billion JPY | 1.33% |
| 2017 FY | 5.84 Billion JPY | 30.66% |
| 2017 Q1 | 4.66 Billion JPY | 4.32% |
| 2017 Q2 | 5.7 Billion JPY | 22.31% |
| 2017 Q3 | 5.76 Billion JPY | 1.06% |
| 2016 FY | 4.47 Billion JPY | 19.63% |
| 2016 Q1 | 4.69 Billion JPY | 25.68% |
| 2016 Q2 | 4.47 Billion JPY | -4.81% |
| 2016 Q3 | 4.3 Billion JPY | -3.84% |
| 2016 Q4 | 4.47 Billion JPY | 4.0% |
| 2015 Q1 | 3.76 Billion JPY | -4.42% |
| 2015 Q3 | 3.74 Billion JPY | -1.86% |
| 2015 Q4 | 3.73 Billion JPY | -0.27% |
| 2015 Q2 | 3.81 Billion JPY | 1.58% |
| 2015 FY | 3.73 Billion JPY | -4.97% |
| 2014 Q2 | 3.07 Billion JPY | 1.05% |
| 2014 FY | 3.93 Billion JPY | 28.2% |
| 2014 Q4 | 3.93 Billion JPY | 7.75% |
| 2014 Q3 | 3.65 Billion JPY | 18.84% |
| 2014 Q1 | 3.04 Billion JPY | -0.92% |
| 2013 Q3 | 2.87 Billion JPY | 1.97% |
| 2013 Q4 | 3.06 Billion JPY | 6.85% |
| 2013 FY | 3.06 Billion JPY | 9.83% |
| 2013 Q1 | 2.76 Billion JPY | -1.07% |
| 2013 Q2 | 2.81 Billion JPY | 1.89% |
| 2012 Q3 | 2.53 Billion JPY | 2.16% |
| 2012 FY | 2.79 Billion JPY | 15.76% |
| 2012 Q1 | 2.35 Billion JPY | -2.41% |
| 2012 Q4 | 2.79 Billion JPY | 10.18% |
| 2012 Q2 | 2.48 Billion JPY | 5.37% |
| 2011 Q1 | 2.36 Billion JPY | -3.94% |
| 2011 Q4 | 2.41 Billion JPY | 1.87% |
| 2011 FY | 2.41 Billion JPY | -1.93% |
| 2011 Q3 | 2.36 Billion JPY | 1.34% |
| 2011 Q2 | 2.33 Billion JPY | -1.11% |
| 2010 Q1 | 2.37 Billion JPY | -10.26% |
| 2010 Q3 | 2.44 Billion JPY | 1.01% |
| 2010 FY | 2.46 Billion JPY | -7.12% |
| 2010 Q4 | 2.46 Billion JPY | 0.78% |
| 2010 Q2 | 2.41 Billion JPY | 1.67% |
| 2009 Q3 | 2.49 Billion JPY | -1.17% |
| 2009 Q2 | 2.52 Billion JPY | 0.0% |
| 2009 Q4 | 2.65 Billion JPY | 6.14% |
| 2009 FY | 2.65 Billion JPY | -2.72% |
| 2008 FY | 2.72 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Takeda Pharmaceutical Company Limited | 15108.79 Billion JPY | 99.758% |
| Sumitomo Pharma Co., Ltd. | 907.5 Billion JPY | 95.97% |
| Shionogi & Co., Ltd. | 1416.91 Billion JPY | 97.419% |
| Wakamoto Pharmaceutical Co.,Ltd. | 15.42 Billion JPY | -137.163% |
| Nippon Shinyaku Co., Ltd. | 263.4 Billion JPY | 86.115% |
| Kaken Pharmaceutical Co., Ltd. | 171.62 Billion JPY | 78.69% |
| Eisai Co., Ltd. | 1393.79 Billion JPY | 97.376% |
| Morishita Jintan Co., Ltd. | 17.18 Billion JPY | -112.844% |
| Hisamitsu Pharmaceutical Co., Inc. | 328.77 Billion JPY | 88.876% |
| Mochida Pharmaceutical Co., Ltd. | 158.8 Billion JPY | 76.969% |
| Fuso Pharmaceutical Industries,Ltd. | 76.46 Billion JPY | 52.167% |
| Nippon Chemiphar Co., Ltd. | 49.54 Billion JPY | 26.187% |
| Tsumura & Co. | 428.25 Billion JPY | 91.46% |
| Kissei Pharmaceutical Co., Ltd. | 260.92 Billion JPY | 85.984% |
| Torii Pharmaceutical Co., Ltd. | 133.43 Billion JPY | 72.591% |
| Towa Pharmaceutical Co., Ltd. | 430.65 Billion JPY | 91.508% |
| Fuji Pharma Co., Ltd. | 85.33 Billion JPY | 57.14% |
| Zeria Pharmaceutical Co., Ltd. | 150.53 Billion JPY | 75.704% |
| KYORIN Holdings, Inc. | 177.67 Billion JPY | 79.416% |
| Taiko Pharmaceutical Co.,Ltd. | 15.04 Billion JPY | -143.075% |
| Daito Pharmaceutical Co.,Ltd. | 77.7 Billion JPY | 52.935% |
| SymBio Pharmaceuticals Limited | 15.35 Billion JPY | -138.229% |
| MedRx Co., Ltd | 2.05 Billion JPY | -1682.31% |
| Mizuho Medy Co.,Ltd. | 18.94 Billion JPY | -93.014% |
| Solasia Pharma K.K. | 2.55 Billion JPY | -1334.235% |
| Modalis Therapeutics Corporation | 2.02 Billion JPY | -1705.249% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 93.31 Billion JPY | 60.806% |
| Sawai Group Holdings Co., Ltd. | 382.02 Billion JPY | 90.427% |
| Cyfuse Biomedical K.K. | 4.21 Billion JPY | -767.726% |
| Toho Holdings Co., Ltd. | 773.42 Billion JPY | 95.271% |
| Koa Shoji Holdings Co.,Ltd. | 32 Billion JPY | -14.276% |